Source comparison
TB-500 Side Effects Long Term Research: Comparison Across Study Durations
4–12 weeks (human trials) Acute injury patients (MI, surgical wounds) Injection site reactions (8–12%), transient headache (5–7%), no serious adverse events reported Small sample sizes (15–47 participants), heterogeneous dosing, limited follow-up beyond treatm
This comparison does not assign a generated winner or score.
- 4–12 weeks (human trials)
- Acute injury patients (MI, surgical wounds)
- Injection site reactions (8–12%), transient headache (5–7%), no serious adverse events reported
- Small sample sizes (15–47 participants), heterogeneous dosing, limited follow-up beyond treatment phase
- Short-term tolerability appears acceptable, but these trials weren't designed to detect cumulative or delayed effects
- 6 months (longest human trial)
- Acute myocardial infarction cohort (IV administration)
- No significant safety signals vs placebo at 180-day endpoint
- Single study, cardiac-specific population, IV route (not subcutaneous), no biomarker tracking for immune or endocrine changes
- Provides best available human data but still insufficient for true long-term safety claims
- 12 months (rodent models)
- Healthy rats, repeated dosing
- No hepatotoxicity, nephrotoxicity, or organ pathology on histological exam
- Species extrapolation limitations, controlled laboratory conditions, lack of real-world variable exposure
- Suggests organ safety at prolonged exposure but doesn't model human immune complexity or genetic variability
- >1 year (no data)
- No published trials
- Unknown
- Absence of data is not evidence of safety
- Critical knowledge gap. This is where chronic use risks would manifest if they exist
- The table underscores the core issue: we have adequate short-term human safety data and adequate long-term rodent safety data, but the intersection. Long-term human safety data. Doesn't exist. Research-grade peptide users are operating in an evidence vacuum beyond the six-month mark.